Home > News > Pioglitazone in Combination with Insulin—An Overview of Results from PROactive
Diabetes
Read Time: 5 mins

Pioglitazone in Combination with Insulin—An Overview of Results from PROactive

Published Online: March 20th 2012 US Endocrinology, 2011;7(2):110-5 DOI: http://doi.org/10.17925/USE.2011.07.02.110
Authors: Bernard Charbonnel
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Pioglitazone provides one of several add-on therapy options for patients with unsatisfactory glycemic control treated with insulin. Although pioglitazone has the beneficial feature of low hypoglycemia risk, it has an overlapping adverse event profile with insulin in terms of edema (with the potential to exacerbate heart failure) and weight gain, leading to possible concern over their use in combination. Fortunately, subgroup analyses from the Prospective pioglitazone clinical trial in macrovascular events (PROactive) have provided valuable insights into the efficacy and safety profile of pioglitazone in patients on established insulin therapy. Pioglitazone improved glycemic control and lipids, while enabling patients to reduce their insulin requirements. With the combination, edema and weight were predictable with no excess exacerbation of heart failure. Importantly, pioglitazone had a good macrovascular safety profile (with a trend toward benefit), consistent with the overall population. This article provides an overview of the results from the insulin-treated subgroup in PROactive and highlights some of the clinical implications for pioglitazone–insulin combination therapy.

Keywords

Type 2 diabetes, pioglitazone, insulin, glycemic control, tolerability, safety, edema, weight gain, heart failure, cardiovascular disease, outcomes

Article:

Many patients with type 2 diabetes require insulin therapy during the course of their disease, either as monotherapy or as an addition to existing oral glucose-lowering therapy.1–3 However, this might not always be sufficient to maintain adequate glycaemic control and additional therapies might therefore be required.1–3 The oral glucoselowering drug pioglitazone is one of several options available for add-on therapy in patients whose glycaemic control remains unsatisfactory on insulin treatment regimens.2–7 Randomised controlled trials (RCTs) have shown that pi

Many patients with type 2 diabetes require insulin therapy during the course of their disease, either as monotherapy or as an addition to existing oral glucose-lowering therapy.1–3 However, this might not always be sufficient to maintain adequate glycaemic control and additional therapies might therefore be required.1–3 The oral glucoselowering drug pioglitazone is one of several options available for add-on therapy in patients whose glycaemic control remains unsatisfactory on insulin treatment regimens.2–7 Randomised controlled trials (RCTs) have shown that pioglitazone provides significant improvements in glycaemic control and lipid profile in insulin-treated patients with type 2 diabetes.8–13 In one recent metaanalysis of four efficacy/safety RCTs, the addition of pioglitazone to insulin therapy provided a 1.22% reduction in glycated haemoglobin (HbA1c) from baseline, as well as a 1.63mmol/L improvement in fasting plasma glucose, a 0.21mmol/L improvement in high-density lipoprotein (HDL) cholesterol, and a 0.05mmol/L improvement in triglycerides.13 The main adverse events associated with pioglitazone in these insulin-treated patients included oedema, weight gain and hypoglycaemia.12,13 Oedema and weight gain are well-characterised adverse events associated with pioglitazone use regardless of background therapy, whereas pioglitazone use per se is generally associated with a low risk of hypoglycaemia.14,15 Improved glycaemic control provided by pioglitazone probably contributes to any increased risk of insulin-induced hypoglycaemia and, at least to some extent, weight gain.14,15 The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) was a landmark cardiovascular (CV) outcomes study looking at the impact of pioglitazone on macrovascular endpoints in high-CV-risk patients with type 2 diabetes.16,17 Since publication of the main results in 2005, PROactive has continued to provide a wealth of information on the CV safety/efficacy profile and metabolic effects of pioglitazone via a range of predefined and posthoc analyses.17–28 Recently, several analyses have looked specifically at the subgroup of patients entering the study on insulin therapy, thus adding considerably to the existing data set on pioglitazone– insulin combination therapy.26–28

This article provide an overview of the key metabolic effects, impact on CV outcomes and the safety/tolerability profile of pioglitazone among insulin-treated patients in PROactive and briefly discusses the clinical implications of these findings. Relevant publications were identified via PubMed searches using the terms ‘pioglitazone AND insulin AND (combination OR addition OR concomitant OR proactive)’.

PROactive – Study Characteristics and Main Overall Findings
PROactive was a randomised, double-blind, multicentre, placebocontrolled, parallel-group study in 5,238 patients with type 2 diabetes and pre-existing macrovascular disease.16 The study looked at the impact of a single glucose-lowering agent (pioglitazone) on macrovascular outcomes compared with placebo when added to background guideline-driven therapy (glucose-lowering and CV medications), thus providing a relatively unambiguous assessment of the CV and metabolic effects of pioglitazone. PROactive remains (at the time of writing) the only completed placebo-controlled outcomes study looking at the effects of a single glucose-lowering drug in type 2 diabetes, although many similar studies are now ongoing (see www.clinicaltrials.gov) in the light of recent regulatory guidelines on the CV safety of glucose-lowering drugs.29,30 PROactive also remains the only completed outcomes study of glucoselowering therapy exclusively in a high-risk population with established macrovascular disease.

PROactive was an event-driven study with an average observation period of 34.5 months. The primary endpoint was a complex composite of macrovascular events, including all-cause mortality, myocardial infarction (MI; including silent MI), stroke, acute coronary syndrome (ACS), endovascular or surgical intervention in the coronary or leg arteries, and amputation above the ankle. In the final analysis for the overall population, there was a trend towards reduced risk in the pioglitazone group for this primary endpoint (HR=0.90, 95% CI [0.80, 1.02], p=0.095). However, there was a significant risk reduction for the predefined main secondary composite outcome of all-cause mortality, MI (excluding silent MI) and stroke [HR=0.84, 95% CI [0.72, 0.98], p=0.27]. Subsequent analyses also showed significant risk reductions for a host of other composite macrovascular endpoints, as well as significant reductions in recurrent MI and recurrent stroke.18,20,22

Analyses of metabolic effects showed that pioglitazone provided a median -0.8% improvement in HbA1c, which was stable throughout the study and significantly greater than the 0.3% reduction seen in the placebo group.16 There were also significant improvements in HDL cholesterol, triglycerides and the low-density lipoprotein (LDL)/HDL ratio compared with placebo.16

When PROactive was designed, oedema (not associated with other signs of heart failure) and heart failure were classified as adverse events of special interest. The incidence of oedema was known to be increased among thiazolidinedione-treated patients and oedema (rather than any direct effect on cardiac function) had been implicated as a potential driver of heart failure events reported in previous studies with this drug class.31,32 As expected, pioglitazone was associated with an increased rate of oedema compared with placebo in PROactive.16 Overall, 26.4% of patients in the pioglitazone group reported non-serious oedema compared with 15.1% in the placebo group, and this led to discontinuation in 2.7 versus 0.8% of patients, respectively. There were only five cases of serious oedema in the pioglitazone group and three in the placebo group. In line with this finding, heart failure was reported in 10.8% of pioglitazone-treated patients versus 7.5% on placebo, whereas serious heart failure was reported in 5.7 versus 4.1%, respectively [HR=1.41, 95% CI (1.10, 1.80), p=0.007].16,19 Reassuringly, however, mortality owing to heart failure was similar with pioglitazone and placebo (0.96 versus 0.84%, p=0.639).19 Furthermore, among those developing serious heart failure, overall mortality rates were also similar between the pioglitazone and placebo groups (26.8 versus 34.3%, p=0.1338) and pioglitazone was associated with a significant reduction in the main secondary endpoint [34.9 versus 47.2%; HR=0.64, 95% CI (0.44, 0.95), p=0.025].19 Thus, the heart failure associated with pioglitazone in PROactive appeared to follow a relatively benign course and did not negate the potential for pioglitazone to reduce macrovascular risk. Overall, the safety and tolerability of pioglitazone was predictable and manageable in line with previous efficacy/safety studies in lower-risk patients.33

Pioglitazone Combination with Insulin in PROactive
Approximately one-third of patients in PROactive were receiving some form of insulin therapy at baseline [864 (33.2%) in the pioglitazone group and 896 (34.0%) on placebo].27 Less than 1% of these patients were on insulin alone, 53% on insulin plus metformin, 24% on insulin plus a sulfonylurea and 12% on insulin plus both metformin and a sulfonylurea, with the remaining 10% on insulin plus at least one other oral agent.27 The mean daily insulin dose was 47U and patients were receiving an average of 2.3 insulin injections/d(23% one injection, 48% two injections and 29% ≥3 injections).27

As expected, the characteristics of the insulin-treated population at baseline differed from the population not receiving insulin (see Table 1).27 Patients on insulin had a longer duration of disease (by ~5 years on average), higher body mass index (by ~1.5kg/m2) and worse glycaemic control (~0.5% higher HbA1c). Furthermore, the incidence of microvascular disease was almost double that seen in patients not receiving insulin. The patients on insulin thus represented a group with more advanced disease who were at particularly high CV risk. Within the insulin-treated subgroup, baseline characteristics were well balanced between the pioglitazone and placebo groups.

Metabolic Findings
Within the insulin-therapy subgroup, pioglitazone was associated with a significant improvement in HbA1c compared with placebo (see Figure 1A).27 Mean HbA1c levels decreased from 8.4 to 7.4% (-0.93%) at the final visit in the pioglitazone group and this was achieved alongside a significant reduction in insulin requirements from a mean of 46.5U/d to 42.1U/d (see Figure 1B).27 This was a significantly greater improvement in HbA1c than in the placebo group (8.5 to 8.1%; -0.45%). It should be noted that the small improvement in the placebo group required an increase in insulin use from 46.7U/d to 54.9U/d. Improvements were achieved after approximately 6 months, were maintained for the duration of the study and were independent of baseline insulin regimen. The magnitude of these effects was similar to that seen in the overall patient population (-0.8% pioglitazone, -0.3% placebo) or those on metformin and/or a sulfonylurea at baseline.16,24,25 As well as decreasing daily insulin requirements, pioglitazone enabled patients to decrease the complexity of their insulin regimens significantly in terms of the number of injections per day compared with placebo.27 Pioglitazone also enabled significantly more patients (8.6%) to discontinue insulin therapy permanently compared with placebo (1.7%, p<0.0001), as well as enabling more patients to discontinue concomitant oral agents.27 In those not using insulin at baseline, significantly fewer patients on pioglitazone (11%) progressed to permanent insulin use compared with placebo [22%; HR=0.47, 95% CI (0.39, 0.56), p<0.0001].16 An analysis compared the more insulin-resistant patients (defined as baseline insulin dose and HbA1c both median or greater) with the less insulin-resistant ones (defined as baseline insulin dose and HbA1c both less than median), the HbA1c/insulin doses ratio at baseline was used as a potential index of insulin sensitivity.27 The median insulin dose at baseline was 42U/d and the median HbA1c was 8.3%. In the patients categorised as less insulin resistant at baseline, the mean baseline HbA1c was 7.3% and insulin dose was 24U/d versus 9.6% and 69U/d in the more insulin-resistant patients (according to their insulin doses and HbA1c both median or greater). In the less insulin-resistant patients, the HbA1c was more or less stable. In the more insulin-resistant patients, it decreased by 1.3% from 9.6 to 8.3% at final visit. In these patients with a baseline HbA1c of 9.6% or more, despite relatively high insulin doses of 69U/d or more, the HbA1c decrease shown in the placebo group was related to the intensification of insulin treatment (mean increase in insulin dose of 7U from 69 to 76U/d, associated with the intensification of the insulin regimen), whereas the greater HbA1c decrease (-1.65 versus -0.92%) on pioglitazone was obtained without any change in the insulin regimen and with lower doses of insulin (mean decrease in insulin units of 11U/d from 68 to 57U/d).

A separate analysis looked at how baseline glucose-lowering therapy affected lipid changes in PROactive.26 In the subgroup of patients on insulin therapy, pioglitazone provided significant improvements in triglycerides and HDL cholesterol compared with placebo (see Figure 3). There were also significant improvements in the LDL/HDL cholesterol ratio. The lipid effects were consistent across all baseline glucose-lowering therapy subgroups, despite the higher baseline HbA1c and longer duration of diabetes in insulintreated patients (see Figure 3).26,27

Cardiovascular Outcomes
The main macrovascular outcomes in the subgroup of patients on insulin at baseline were consistent with the results reported for the overall population (see Figures 2A and 2B).16,27 For the primary composite endpoint, there was a non-significant trend towards benefit with pioglitazone compared with placebo [HR=0.86, 95% CI (0.70, 1.02), p=0.1173]. There was also a trend towards benefit for the main secondary composite endpoint [HR=0.85, 95% CI (0.67, 1.08), p=0.1783].27 Although a significant reduction was seen for this secondary endpoint in the overall population, there was less power to detect any differences in the smaller insulin-treated subgroup. A separate analysis also investigated whether the impact of pioglitazone on CV risk differed between those on insulin and those not on insulin at baseline (see Table 2).28 The impact on the primary and main secondary outcomes (as well as the composite of CV mortality, MI and stroke) was similar regardless of baseline insulin use, and there were no significant interactions between the subgroup and randomised treatments. The main CV endpoint outcomes described above thus demonstrate that, as in the overall PROactive population, pioglitazone therapy is associated with a trend towards a macrovascular benefit compared with placebo when added to insulin therapy.Safety and Tolerability
The CV outcomes results also demonstrate clearly that pioglitazone has a good macrovascular safety profile among insulin-treated patients, as seen in the overall PROactive population.33 The adverse event profile of pioglitazone was similar to placebo, with the exceptions of oedema and hypoglycaemia, which were more frequent with pioglitazone, the latter being consistent with better glycaemic control in the pioglitazone group.27,28

As both insulin and pioglitazone individually are associated with oedema, and thus possible exacerbation of heart failure, these two aspects of safety and tolerability were of particular interest in the insulin-therapy subgroup in PROactive. Previous clinical studies suggested that the oedema risk is greater when pioglitazone is added to insulin,12,31 which might relate to the two therapies affecting fluid retention in different bodily compartments (mainly extracellular and extravascular with pioglitazone, but intravascular with insulin).34 However, although pioglitazone increased oedema in the insulin-treated subgroup in PROactive (~80% relative increase in risk versus placebo), an almost identical increase in risk was seen in the non-insulin-treated subgroup (see Table 2).27,28 Furthermore, in absolute terms, the risk of oedema was only increased slightly in patients receiving insulin versus those not receiving insulin in either the pioglitazone (23.6 versus 20.6%, respectively, for oedema in the absence of heart failure) or placebo groups (14.1 versus 12.4%).28 Notably, there were only four events of serious oedema among insulin-treated patients in the pioglitazone group and two in the placebo group.27 Thus, in the PROactive population, the increase in oedema associated with pioglitazone therapy was predictable irrespective of baseline insulin therapy and insulin therapy itself had only a minor impact.

Overall rates of heart failure were significantly higher in insulintreated (12.0%) versus non-insulin-treated patients (7.7%, p<0.0001), which suggests that, for whatever reasons (longer duration of the disease, poorer control, insulin itself, etc.), insulin-treated patients are at higher risk for heart failure. Within the insulin-treated group, heart failure events were reported more often with pioglitazone (13.5 versus 10.5% for placebo, p<0.05).27 Although the risk of serious heart failure with pioglitazone relative to placebo was consistent with the increased risk seen in the overall population, it did not appear to be enhanced among insulin-treated patients [HR=1.21, 95% CI (0.82, 1.79), p=0.3430; see Table 2].28 In absolute terms, rates of serious heart failure associated with pioglitazone were not significantly different in insulin and non-insulin-treated patients (6.3 versus 5.5%, respectively) and the placebo rate among insulin-treated patients (5.2%).27,28 Rates of fatal heart failure among insulin-treated patients were similar for pioglitazone and placebo (1.4 versus 1.1%, respectively).27 Oedema might also be one of the factors contributing to the weight gain typically associated with pioglitazone or insulin.33 In the insulintherapy subgroup, pioglitazone was associated with a 4.2kg increase in body weight from baseline, which was marginally greater than the +3.6kg seen in the overall population.16,26 Weight gain correlated with the decline in HbA1c, consistent with a calorie-sparing effect from better glycaemic control.15 Most of the weight gain occurred within the first year and stabilised within the second year.16 The magnitude of this weight gain is consistent with previous long-term (2–3 year) studies of pioglitazone as either monotherapy or add-on therapy to other glucose-lowering agents, where increases of 2.5–5kg have been reported.35–37 In shorter-term studies (≤6 months) looking specifically at pioglitazone add-on to insulin, weight gain of approximately 4kg has typically been reported.8–12 By contrast, weight remained stable (-0.1kg change) among insulin-treated patients in the placebo group (similar to the -0.4kg change in the overall population), suggesting that any insulin-associated weight change had stabilised by the start of the study.

Insulin-treated patients would be expected to experience more hypoglycaemic events than those not requiring insulin,38 and this was confirmed in PROactive (all hypoglycaemia, 35.5 versus 18.4%, respectively; serious hypoglycaemia, 1.3 versus 0.3%).27 Within the insulin subgroup, pioglitazone-treated patients also had a higher rate of hypoglycaemia compared with placebo (all hypoglycaemia, 42.1 versus 29.0%, respectively; serious hypoglycaemia, 1.9 versus 0.8%) consistent with better glycaemic control.27 Baseline sulfonylurea use did not influence hypoglycaemia rates.27

Conclusions
PROactive remains the only completed placebo-controlled CV outcomes study looking at the effects of a single glucose-lowering agent in type 2 diabetes and the only study exclusively in a high-CVrisk population with established macrovascular disease. With the results of PROactive alongside meta-analyses of efficacy/safety RCTs and large-scale surrogate CV endpoints studies (utilising carotid intima media thickness [cIMT] measurements and coronary vessel intravascular ultrasound), pioglitazone has one of the best characterised CV profiles of any glucose-lowering agent.33,39–41 Overall, the evidence suggests that pioglitazone has good CV safety and could even provide some macrovascular benefit. The recent subgroup analyses from PROactive described here now extend these findings specifically to pioglitazone as an add-on therapy to insulin and suggest a similar good CV profile and trend towards macrovascular benefit in this patient population. This is particularly important in insulin-treated patients as they tend to have more advanced disease and thus represent a more vulnerable population with higher CV risk. From a metabolic perspective, pioglitazone provided improvements in glycaemic control and lipids that were consistent irrespective of baseline glucose-lowering therapy. The improvements in HDL cholesterol provided by pioglitazone might be particularly relevant as this appears to be the one of the main drivers of the antiatherosclerotic effects of pioglitazone (based on analysis of the ability of pioglitazone to slow cIMT progression in the CHICAGO study).42 Clearly, pioglitazone might not be the most appropriate option in all patients on insulin therapy. However, the subgroup analyses from PROactive suggest that some of the key pioglitazone-associated factors that warrant consideration (notably oedema and weight gain) are predictable and have essentially the same impact irrespective of whether a patient is on insulin therapy. Patients already with oedema or excessive body weight might not be good candidates, as pioglitazone would be expected to exacerbate these factors irrespective of insulin therapy, but in the absence of these factors, pioglitazone might be a more viable option, especially in insulinresistant patients with a poor glycaemic control despite high doses of insulin. Clinicians can also be relatively confident that the risk of exacerbating heart failure with pioglitazone is no greater in insulintreated patients and it should also be remembered that any pioglitazone-associated heart failure that might occur appears to follow a relatively benign course with no adverse impact on mortality or macrovascular outcomes. In patients with pre-existing heart failure, however, pioglitazone is contraindicated.4,5 By contrast, pioglitazone might be a particularly appropriate option in some specific insulin-treated patient populations. For instance, pioglitazone is often used as an addition to insulin in lean Japanese patients, as metformin appears to be less effective in terms of glucose control in this population.7

One point that should be considered when interpreting these results from PROactive is that they relate to addition of pioglitazone to insulin therapy and not addition of insulin to pioglitazone, which might occur in clinical practice as part of the standard stepwise approach to therapy.2,3,43 The value of adding exogenous insulin to ongoing pioglitazone therapy still needs to be evaluated, as well as the potential benefit of initiating combined insulin and pioglitazone therapy early in the course of the disease. The impact on weight gain and risk of oedema might be more significant in patients naïve to both therapies. Furthermore, the analyses from PROactive only relate to baseline insulin use and not to on-treatment insulin use. Nevertheless, the results demonstrate that the efficacy/tolerability profile of pioglitazone as an add-on to established insulin therapy is consistent with previous shorter term RCTs.8–13 Any increases in hypoglycaemia would appear to be consistent with the improved glycaemic control provided by pioglitazone.

In conclusion, subgroup analyses of insulin-treated patients from PROactive show that addition of pioglitazone represents an effective, insulin-sparing glucose-lowering therapy with a good CV safety profile. Furthermore, the predictability of potential tolerability issues of weight gain, oedema and exacerbation of heart failure seen in PROactive should be of benefit to clinicians when making decisions regarding the appropriateness of pioglitazone therapy for individual insulin-treated patients.

Article Information:
Disclosure

Bernard Charbonnel, MD, was a member of the PROactive Executive Committee and has received fees for consultancy, speaking, travel, and accommodation from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Merck, Sharpe & Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis and Takeda.

Correspondence

Bernard Charbonnel, MD, Clinique d’Endocrinologie, Maladies Métaboliques et Nutrition, CHU de Nantes, Hôtel Dieu, 1 place Alexis Ricordeau, 44093 Nantes Cedex 1, France. E: bernard.charbonnel@univ-nantes.fr

Received

2011-01-11T00:00:00

References

  1. Horton ES, Defining the role of basal and prandial insulin for optimal glycemic control, J Am Coll Cardiol, 2009;53(Suppl. 5):S21–7.
  2. Rodbard HW, Jellinger PS, Davidson JA, et al., Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract, 2009;15(6):540–59.
  3. German Diabetes Association, Matthaei S, Bierwirth R, et al., Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association, Exp Clin Endocrinol Diabetes, 2009;117(9):522–57.
  4. Anon, Actos (Pioglitazone Hydrochloride) Summary of Product Characteristics. London, Takeda Global Research and Development Centre (Europe) Ltd, 2009.
  5. Anon, Actos (Pioglitazone Hydrochloride) Tablets U.S. Prescribing Information. Deerfield, Takeda Pharmaceuticals America, Inc., 2009.
  6. . Huang A, Raskin P, Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus, Treat Endocrinol, 2005;4(4):205–20.
  7. Yamanouchi T, Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes, Vasc Health Risk Manag, 2010;6:189–97.
  8. Mattoo V, Eckland D, Widel M, et al., Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallelgroup study, Clin Ther, 2005;27(5):554–67.
  9. Rosenstock J, Einhorn D, Hershon K, et al., Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy, Int J Clin Pract, 2002;56(4):251–7.
  10. Davidson JA, Perez A, Zhang J, et al., Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study, Diabetes Obes Metab, 2006;8(2):164–74.
  11. Berhanu P, Perez A, Yu S, Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy, Diabetes Obes Metab, 2007;9(4):512–20.
  12. Clar C, Royle P, Waugh N, Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis, PLoS One, 2009;4(7):e6112.
  13. Tan A, Cao Y, Xia N, et al., The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a metaanalysis, Eur J Intern Med, 2010;21(5):398–403.
  14. Derosa G, Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents, Drugs, 2010;70(15):1945–61.
  15. Hermansen K, Mortensen LS, Body weight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus, Drug Saf, 2007;30(12):1127–42.
  16. Dormandy JA, Charbonnel B, Eckland DJ, et al., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 2005;366(9493):1279–89.
  17. Betteridge DJ, DeFronzo RA, Chilton RJ, PROactive: time for a critical appraisal, Eur Heart J, 2008;29(8):969–83.
  18. Wilcox R, Bousser M-G, Pirag V, et al., Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04), Stroke, 2007;38(3):865–73.
  19. Erdmann E, Charbonnel B, Wilcox RG, et al., Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08), Diabetes Care, 2007;30(11):2773–8.
  20. Erdmann E, Dormandy JA, Charbonnel B, et al., The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study, J Am Coll Cardiol, 2007;49(17):1772–80.
  21. Schneider CA, Ferrannini E, DeFronzo R, et al., Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease, J Am Soc Nephrol, 2008;19(1):182–7.
  22. Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators, Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10), Am Heart J, 2008;155(4):712–7.
  23. Dormandy JA, Betteridge DJ, Schernthaner G, et al., Impact of peripheral arterial disease in patients with diabetes – results from PROactive (PROactive 11), Atherosclerosis, 2009;202(1):272–81.
  24. Scheen AJ, Tan MH, Betteridge DJ, et al., Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17), Diabet Med, 2009;26(10):1033–9.
  25. Scheen AJ, Tan MH, Betteridge DJ, et al., Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18), Diabet Med, 2009;26(12):1242–9.
  26. Spanheimer R, Betteridge DJ, Tan MH, et al., Long-term lipid effects of pioglitazone by baseline anti-hyperglycemic medication therapy and statin use from the PROactive experience (PROactive 14), Am J Cardiol, 2009;104(2):234–9.
  27. Charbonnel B, DeFronzo R, Davidson J, et al., Pioglitazone use in combination with insulin in the prospective pioglitazone clincal trial in macrovascular events study (PROactive19), J Clin Endocrinol Metab, 2010;95(5):2163–71.
  28. Erdmann E, Spanheimer R, Charbonnel B; PROactive Study Investigators, Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20), J Diabetes, 2010;2:212–20.
  29. US Food and Drug Administration, Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Silver Spring, FDA, 2008.
  30. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus [Draft]. London, European Medicines Agency, 2010.
  31. Tang WH, Do thiazolidinediones cause heart failure? A critical review, Cleve Clin J Med, 2006;73(4):390–7.
  32. Erdmann E, Wilcox RG, Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure, Eur Heart J, 2008;29(1):12–20.
  33. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, PROactive investigators, Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive, Drug Saf, 2009;32(3):187–202.
  34. Mudaliar S, Chang AR, Aroda VR, et al., Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes, Diabetes Obes Metab, 2010;12(2):133–8.
  35. Tan MH, Baksi A, Krahulec B, et al., Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes, Diabetes Care, 2005;28(3):544–50.
  36. Charbonnel B, Schernthaner G, Brunetti P, et al., Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes, Diabetologia, 2005;48(6):1093–104.
  37. Tolman KG, Freston JW, Kupfer S, Perez A, Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US, Drug Saf, 2009;32(9):787–800.
  38. Barnett AH, Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy, Curr Med Res Opin, 2010;26(6):1333–42.
  39. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials, JAMA, 2007;298(10):1180–8.
  40. Mazzone T, Meyer PM, Feinstein SB, et al., Effect of pioglitazone compared with glimepiride on carotid intimamedia thickness in type 2 diabetes: a randomized trial, JAMA, 2006;296(21):2572–81.
  41. Nissen SE, Nicholls SJ, Wolski K, et al., Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial, JAMA, 2008;299(13):1561–73.
  42. Davidson M, Meyer PM, Haffner S, et al., Increased highdensity lipoprotein cholesterol predicts the pioglitazonemediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus, Circulation, 2008;117(16):2123–30.
  43. Nathan DM, Buse JB, Davidson MB, et al., Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia, 2009;52(1):17–30.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72